• 1
    Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425432.
  • 2
    Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 16451654.
  • 3
    Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 34473453.
  • 4
    Spano JP, Costagliola D, Katlama C et al. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26: 48344842.
  • 5
    Patel P, Hanson DL, Sullivan PS et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728736.
  • 6
    Engels EA, Biggar RJ, Hall HI et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187194.
  • 7
    Lima VD, Hogg RS, Harrigan PR et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685692.
  • 8
    Bonnet F, Burty C, Lewden C et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48: 633639.
  • 9
    Marin B, Thiebaut R, Bucher HC et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23: 17431753.
  • 10
    Hessol NA, Seaberg EC, Preston-Martin S et al. Cancer risk among participants in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 36: 978985.
  • 11
    Phelps RM, Smith DK, Heiling CM et al. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94: 753757.
  • 12
    Murillas J, Del Rio M, Riera M et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16: 113115.
  • 13
    De Falco G, Bellan C, Lazzi S et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene 2003; 22: 62146219.
  • 14
    International Agency for Research on Cancer (IARC) Working group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the evaluation of carcinogenic risks to humans. 1997; volume 70: Epstein-Barr Virus and Kaposi's sarcoma Herpes virus/HumanHerpesvirus.
  • 15
    International Agency for Research on Cancer (IARC) Working group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the evaluation of carcinogenic risks to humans. 1994; volume 59: Hepatitis viruses.
  • 16
    International Agency for Research on Cancer (IARC) Working group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the evaluation of carcinogenic risks to humans. 2005; volume 90: HumanPapillomaviruses.
  • 17
    Calabresi A, Ferraresi A, Limina RM et al. A population-based database to study malignancies in HIV-infected patients in the Local Agency of Brescia between 1999 and 2009. Epidemiol Prev 2011 [Epub ahead of print].
  • 18
    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinoma in the United States. J Clin Oncol 2008; 26: 612619.
  • 19
    Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies. International Agency for Research of Cancer (IARC) scientific publication 1987; No 82, vol II.
  • 20
    Regione Lombardia/ASL Brescia. Documento di programmazione e coordinamento dei servizi sanitari e socio-sanitari dell'ASL di Brescia per l'anno 2012. Available at (accessed 25 September 2012).
  • 21
    Centro Operativo AIDS. Aggiornamento delle nuove diagnosi di infezione da HIV al 31 dicembre 2009 e dei casi di AIDS in Italia al 31 dicembre 2010. Supplemento del notiziario dell'Istituto Superiore di Sanità 2011; 24: 132.
  • 22
    Polesel J, Franceschi S, Suligoi B et al. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127: 14371445.
  • 23
    Dal Maso L, Polesel J, Serraino D et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100: 840847.
  • 24
    Prosperi MC, Cozzi-Lepri A, Castagna A et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 13161321.
  • 25
    Vogel M, Friedrich O, Lüchters G et al. Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 2011; 16: 101107.
  • 26
    Kesselring A, Gras L, Smit C et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52: 14581465.
  • 27
    Reekie J, Kosa C, Engsig F et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 53065315.
  • 28
    Franceschi S, Lise M, Clifford GM et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103: 416422.
  • 29
    Lewden C. Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121130.
  • 30
    Cohen MH, French AL, Benning L et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113: 9198.
  • 31
    Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002; 186: 10231027.
  • 32
    Grulich AE. Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009; 4: 183187.
  • 33
    Cáceres W. Cruz-Amy M, Díaz-Meléndez V. AIDS-related malignancies: revisited. P R Health Sci J 2010; 29: 7075.
  • 34
    Chao C, Leyden WA, Xu L et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012; 26: 22232231.
  • 35
    Guiguet M, Boue F, Cadranel J et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 11521159.
  • 36
    Crum-Cianflone N, Hullsiek KH, Marconi V et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23: 4150.
  • 37
    Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884890.